Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03855774
Other study ID # PDH-1-SMO-2-0509-op1
Secondary ID IDRCB
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2018
Est. completion date December 1, 2018

Study information

Verified date February 2019
Source Institut de Recherche Biomedicale des Armees
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Screening of a population of volunteer workers recruited on the occasion of their occupational health visit, within the Ministry of Defense and civil enterprises.

The voluntary subjects included will, after signing a consent, take a saliva sample (Kit Oragen DNA OG500) and fill out a computerized questionnaire.

A posteriori, the genotyping polymorphisms may be associated with variations in the pharmacokinetics or pharmacodynamics of caffeine will be achieved.

The primary objective is to determine whether polymorphisms (alone or in combination) of genes associated with the pharmacokinetics or pharmacodynamics of caffeine are independent risk factors for sleep disorders.

The secondary objectives are to determine the frequency of these polymorphisms and to evaluate the consequences of these associations on sleep habits (sleep time, chronotype, quality of sleep), daytime sleepiness, caffeine consumption, antecedents of accidents at work or traffic, drug consumption ...


Description:

Coffee is one of the most consumed drinks in the world and its consumption has doubled in 20 years. Because of the health benefits of caffeine (present in many foods and medicines), but also adverse effects, its physiological actions deserve to be better known and its use better framed.

Indeed, caffeine is the most used psychoactive substance to prevent the deterioration of the cognitive performance of night workers and soldiers in operation. Its "strategic" use is even recommended in many armies. In its sustained-release dosage form (Caffeine 300 mg), it is the only drug, increasing alertness, authorized in the French military. Caffeine also has beneficial effects on inflammatory response, muscle activity, insulin sensitivity, cardiovascular risk, weight gain, neuroprotection, chronic pain. Usual consumption of 2 to 3 coffees a day is recommended by the American Nutrition Society.

However, coffee consumption is associated with many side effects such as anxiety, sleep disorders, increased blood pressure, cardiovascular and obstetric conditions or depression. Many authors therefore recommend limiting its use. In particular, it is considered a risk factor for sleep disorders such as insomnia.

The physiological effects and sensitivity to side effects of caffeine are characterized by very high individual variability3 related to age, sex, habitual coffee consumption, smoking, but also to genetic polymorphisms. Indeed, multiple polymorphisms are associated with changes in pharmacokinetics (see Table 1) or pharmacodynamics (efficacy, see Table 2) of caffeine. Sensitivity to caffeine is associated in particular with greater vulnerability to sleep deprivation, sleep disorders and stress.n particular, polymorphisms of the adenosine receptor (ADORA) gene, a therapeutic target for caffeine, are particularly involved in the individual variability of caffeine sensitivity, side effects and consumption habits. But many other polymorphisms of genes encoding enzymes involved in metabolism or physiological effects are also associated with the individual variability of caffeine.

On the other hand, some gene polymorphisms such as the adenosine deaminase gene (ADA) which degrades caffeine and regulates intra- and extracellular concentrations, are associated with greater vulnerability to sleep deprivation, without the effects on caffeine sensitivity are known.

Currently, it is difficult to assess the impact of these polymorphisms on the beneficial effects and / or risks associated with caffeine consumption due to their number and lifestyle, including coffee consumption. In other words, are sleep disorders favored by polymorphism and / or habitual consumption of caffeine? Are there profiles of high vulnerability to sleep deprivation and sensitivity to caffeine? Do these polymorphisms have a link with burnout, work stress, diseases?


Recruitment information / eligibility

Status Completed
Enrollment 1100
Est. completion date December 1, 2018
Est. primary completion date January 1, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- active workers

Exclusion Criteria:

- inactive subject (unemployed, student...)

- involuntary subject

Study Design


Intervention

Genetic:
Polymorphisms
Classification of sleep disorders using 22 genetic polymorphisms

Locations

Country Name City State
France Fabien SAUVET Bretigny sur Orge

Sponsors (1)

Lead Sponsor Collaborator
Institut de Recherche Biomedicale des Armees

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Polymorphisms and sleep disorders Sleep disorders frequency by genetic polymorphism 1 salivary sample (screening)
Secondary Sleep duration Total sleep time (hours) in function of polymorphisms 1 salivary sample (screening)
See also
  Status Clinical Trial Phase
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Recruiting NCT04786314 - The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome N/A
Recruiting NCT05775731 - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Recruiting NCT03326765 - Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC) N/A
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT03903263 - Sleep Disturbances in Dermatology Patients
Not yet recruiting NCT06012513 - Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis
Not yet recruiting NCT05950932 - Effects of Melissa Extract on Sleep Characteristics Phase 4
Completed NCT01463839 - Sleep Disorder and Oral Habits in Children N/A
Completed NCT00940589 - Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor Phase 2
Recruiting NCT06093633 - A Prospective Study to Evaluate the WP in Comparison to PSG in Patients Suspected of Sleep Disorders
Completed NCT06108115 - Smartphone-Based Intervention for Sleep Disturbance in Individuals Recovering From Alcohol Use Disorder N/A
Completed NCT05511818 - Radicle Rest: A Study of Cannabinoids on Sleep and Health Outcomes N/A
Active, not recruiting NCT04291014 - Light Therapy for PD - Dose Selection N/A
Completed NCT04560595 - Remote Guided Caffeine Reduction N/A
Completed NCT06008470 - Investigation of Respiratory Muscle Strength, Exercise Capacity, Physical Activity and Sleep Quality Level in Individuals With Covid-19 Infection
Recruiting NCT06129942 - Light Therapy in Parkinson's Disease N/A
Recruiting NCT04318067 - Melatonin in ADHD and Sleep Problems Phase 4
Completed NCT03532269 - Validation of the Sleep Assessment Algorithm in the Medical Application Nightly N/A
Completed NCT03857802 - Efficiency of a Nursing Intervention in Sleep Hygiene N/A